[19] Tabernero J，Hoff PM，Shen L，et al. Pertuzumab plus tra-stuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB)：final analysis of a double-blind，randomised，placebo-controlled phase 3 study [J]. Lancet Oncol，2018， 19(10)：1372-1384.

    [20] Shitara K，Hara H，Yoshikawa T，et al. Pertuzumab plus trastuzumab and chemotherapy for Japanese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer：a subgroup analysis of the JACOB trial [J]. Int J Clin Oncol ......